Akeso's proposition is to develop BsAb as a universal anti-cancer drug. Its revenue from Cadonilimab in the out-of-hospital market for Cervical Cancer is unique. Price elasticity is likely post NDRL
What is covered in the Full Insight:
Market Share and Competitive Positioning
Price Cuts and NDRL Inclusion
Patient Base and Market Potential
Drug Development and Approvals
Future Outlook and Opportunities
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.